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Introduction
The burden of obesity continues to be great, with more than 35% of Americans now classified as obese [3, 16] . As the epidemic continues to increase, patients with obesity are of particular concern to arthroplasty surgeons. Obesity not only is associated with an increased risk of knee osteoarthritis, but also with a younger age for primary TKA in patients who are obese than in patients who are not obese [22] . Furthermore, obesity is associated with a higher risk of postoperative complications and need for revision surgery after primary TKA, particularly in patients with morbid obesity (BMI C 40 kg/m 2 ) [5, 11] .
Revision TKA for aseptic failure provides reliable and durable improvement in patient pain and function, with long-term implant survival rates between 80% and 94% [2, 7, 9, 12, 20, 23, 25, 26] . However, to our knowledge, no studies have specifically reported on survivorship or functional scores after aseptic revision TKA in patients with morbid obesity.
The purpose of our study was to evaluate the outcomes of revision TKA performed for aseptic reasons in patients with morbid obesity with those with a BMI less than 30 kg/ m 2 . Specifically, we aimed to answer the questions: (1) Are patients with morbid obesity at greater risk of repeat revision, reoperation, or periprosthetic joint infection (PJI) compared with patients without obesity after an index revision TKA performed for aseptic reasons? (2) Do patients who are not obese achieve higher Knee Society pain and function scores after revision TKA for aseptic reasons than patients with morbid obesity?
Patients and Methods

Study Design
We conducted a single-center, retrospective, 1:1 matched cohort analysis after obtaining approval from our institutional review board. Our institutional total joint registry, which prospectively captures survival data and patient outcomes, was used to identify 1291 both-component index revision TKAs performed for aseptic reasons during a 15year period (1992-2007), including 120 in patients with morbid obesity and 624 in patients with a BMI less than 30 kg/m 2 . Exclusion criteria included any prior revision TKA on the same knee, previous diagnosis of PJI on the same knee, single-component revision, and conversion from a unicompartmental knee arthroplasty to a TKA. We then considered only patients with a minimum of 5 years followup, which was available for 77% of patients with morbid obesity and 76% with a BMI less than 30 kg/m 2 (p = 0.84). All (n = 93) patients with morbid obesity were included (morbid obesity group) and matched with a cohort of 93 patients with a BMI less than 30 kg/m 2 (nonmorbid obesity group) using age (± 3 years), date of revision TKA (± 2 years), and sex (Table 1) . Primary outcome measures included rerevision surgery (subsequent removal or exchange of femoral and/or tibial components), reoperation for any reason, and subsequent PJI. All diagnoses of PJI met the International Consensus on Periprosthetic Joint Infection criteria [17] . Clinical outcomes were reported for each group, including Knee Society pain and function scores. Patient outcomes were unknown at the time of patient matching.
Patients
There were 93 patients in each group (morbid obesity and nonmorbid obesity), with each group including 70 (75%) women. The average age of the patients was 66 years (range, 45-84 years) in the morbid obesity group and 66 years (range, 44-85 years) in the nonmorbid obesity group. There were more patients with Type II diabetes mellitus in the morbid obesity group (25% vs 11%; p \ 0.02) and more with rheumatoid arthritis in the nonmorbid obesity group (12% vs 2%; p \ 0.01). No patients in either group had Type I diabetes mellitus. There were six (6%) current smokers in each group. The indications for index revision TKA did not appear to change with time during the study period; the most common reason for revision was aseptic loosening in both groups ( Table 1 ). The average followup was 7.9 years (range, 5-18 years) and 7.3 years (range, 5-16 years) for the morbid obesity and nonmorbid obesity groups, respectively (p = 0.73).
Before revision, PJI was excluded in all knees using serum inflammatory markers and knee aspiration when indicated. Revision TKA was performed using techniques and implants at the discretion of the treating surgeon ( Table 2 ). There were no differences between the two groups with respect to implant constraint, use of stems, type of stem fixation, augments, or the use of adjunctive metaphyseal fixation (sleeves or cones) at the time of revision TKA. Simplex TM P cement (Stryker Corporation, Mahwah, NJ, USA) mixed with vancomycin and/or aminoglycoside antibiotics were used in all patients. For each group, a median of 1 g per batch of vancomycin (range, 0-1 g/batch) and 1.2 g per batch of aminoglycoside (range, 0-1.2 g/batch) were used.
Statistics
Descriptive statistics are reported as number (percentage), and continuous variables are reported as mean (standard deviation). Cox proportional regression analysis was performed to assess the association of morbid obesity with the risk of subsequent revision, reoperation, and PJI, with results reported as hazard ratios (HR) with 95% CI. Multivariate analysis could not be performed owing to the limited number of events, but given the differing prevalences of diabetes mellitus and rheumatoid arthritis between groups, adjusted risk also was assessed to control for the presence of diabetes mellitus and rheumatoid arthritis. Kaplan-Meier survival estimates were used to describe the cumulative probability of the same outcomes, with results reported as a percentage with 95% CI. Log-rank tests were performed to determine statistical significance of survival estimates. Kaplan-Meier estimates were not affected by differences in patient mortality; eight (7%) patients in the morbid obesity group died at a mean of 11 years after revision, which was similar to 10 (11%) deaths in the nonmorbid obesity group at a mean of 10 years (p = 0.66). All statistical calculations were made using JMP 1 version 9 (Statistical Analysis Software, Cary, NC, USA) with a-level set at 0.05.
Results
Association of Morbid Obesity with Repeat Revisions, Reoperations, and PJI
We found that patients with morbid obesity were at greater risk of repeat revision, reoperation, and PJI when compared with patients with a BMI less than 30 kg/m 2 . Repeat revision was performed in 14 patients (15%) with morbid obesity compared with three (3%) who were not obese (adjusted HR, 3.2; 95% CI, 1.1-14.0; p \ 0.04). An equal proportion of repeat revisions were performed for PJI and aseptic loosening in the morbid obesity group, whereas all repeat revisions were performed for aseptic loosening in the nonmorbid obesity group. Kaplan-Meier estimates for revision-free survival were 96% (range, 92%-100%) at 5 years and 81% (range, 70%-92%) at 10 years for the morbid obesity group compared with 100% at 5 years and 93% (range, 86%-100%) at 10 years for the nonmorbid obesity group (p = 0.02) ( Fig. 1A) . Reoperation for any reason was performed in 24 patients (26%) in the morbid obesity group compared with seven (8%) in the nonmorbid obesity group (adjusted HR, 2.4; 95% CI, 1.1-6.2; p \ 0.03). Kaplan-Meier estimates for reoperation-free survival were 89% (range, 83%-95%) and 71% (range, 59%-83%) at 5 and 10 years for the morbid obesity group, and 99% (range, 98%-00%) and 85% (range, 75%-95%) at 5 years and 10 years for the nonmorbid obesity group (p = 0.009) ( Fig. 1B) . PJIs also were more frequent in patients with morbid obesity (9% vs 1%; p \ 0.02), with a trend toward increased risk (adjusted HR, 4.4; 95% CI, 0.8-82.2; p = 0.10) ( Table 3) . Kaplan-Meier estimates for survival free of PJI were 98% (range, 96%-100%) and 100% at 5 years and 87% (range, 77%-97%) and 100% at 10 years for the morbid obesity group and nonmorbid obesity group, respectively (p = 0.04) (Fig. 1C) .
Morbid Obesity and The Knee Society Scores
The Knee Society scores (with 95% CIs) improved after surgery in both groups; however, patients in the nonmorbid obesity group had better pain and function scores than patients in the morbid obesity group at 2, 5, and 10 years (p \ 0.01) ( Table 4 ). At last followup, there were 39 (42%) and 13 patients (14%) with moderate or severe pain in the morbid obesity group, and 37 (40%) and 25 patients (27%) who reported having either moderate or severe functional limitations in the morbid obesity and nonmorbid obesity groups, respectively.
Discussion
It is well documented that patients with obesity have more frequent complications and a greater risk of revision after primary TKA [4, 5, 14, 15] . As the prevalence of obesity increases, these complications will continue to create The estimated survival free of subsequent revision was 81% (95% CI, 70%-92%) for the patients in the morbid obesity group and 93% (95% CI, 86%-100%) for patients in the nonmorbid obesity group at 10 years (p = 0.02). (B) The estimated survival free of reoperation was 71% (95% CI, 59%-83%) for the patients in the morbid obesity group and 85% (95% CI, 75%-95%) for patients in the nonmorbid obesity group at 10 years (p = 0.009). (C) The estimated survival free of periprosthetic joint infection was 87% (95% CI, 77%-97%) for patients in the morbid obesity group and 100% for patients in the nonmorbid obesity group at 10 years (p = 0.04).
challenges for arthroplasty surgeons. To date, we have a better understanding of the effect of obesity on the outcome of primary TKA compared with the effect on revision TKA. Watts et al. [24] reported on the outcomes of twostage revision for infection in patients with morbid obesity.
In the current study, we evaluated the survivorship and The Knee Society Scores for revision TKA performed in patients with morbid obesity for aseptic reasons. We found that patients with morbid obesity (BMI C 40 kg/m 2 ) had higher rates of subsequent revision, reoperation, and deep infection after aseptic revision TKA when compared with a matched cohort of patients with a BMI less than 30 kg/m 2 .
The results of our study should be interpreted in light of certain limitations. Foremost, although our data were prospectively collected, it was examined retrospectively and included only patients in whom the femoral and tibial components were revised. Second, as we practice at a tertiary referral center, many of our patients had prior care at outside institutions, which created a possibility for selection bias. Furthermore, our study was performed at one institution by different surgeons, with reconstruction methods and techniques based on surgeon preference which may have evolved with time. Finally, BMI is inherently associated with systemic comorbidities, which makes it impossible to prove a causal relationship between BMI and outcomes. As an example, there were more patients with diabetes mellitus in the morbid obesity group (25% vs 11%) and more with rheumatoid arthritis in the nonmorbid obesity group (12% vs 2%). To account for these differences, we reported an adjusted risk analysis that accounted for diabetes mellitus and rheumatoid arthritis, although disease severity was not taken into account. Important variables such as fat distribution, immune suppression, and nutrition status were not quantified.
We found implant survivorship at 5 and 10 years of 96% and 81%, respectively, in the morbid obesity group compared with 100% and 93% in the nonmorbid obesity group. Although there are no data for comparison regarding aseptic revision in patients with obesity, these implant survival rates are better than those reported for patients with morbid obesity after two-stage revision TKA for infection (80% and 55% at 5 and 10 years, respectively) [24] . In the current study, morbid obesity was associated with a 3.8-fold increase in risk of rerevision. This finding is (14) 23 (25) Severe 0 (0) 2 (2) consistent with those of a meta-analysis of primary TKAs which showed that patients with a BMI of 30 kg/m 2 or greater had a 1.8-fold increase in the risk of revision surgery compared with patients with a BMI less than 30 kg/ m 2 [11] . There is little agreement in the literature regarding the most common reason for failure of revision TKAs [6, 14, 18, 19, 21] . In our study, deep infection was the most common cause of revision and reoperation in the patients with morbid obesity, whereas patients with a BMI less than 30 kg/m 2 were most likely to experience failure of the after revision TKA secondary to aseptic loosening. Mortazavi et al. reported a deep infection rate of 4.4% after revision TKAs in patients with no prior history of infection [14] . In comparison, 8.6% of the patients in our morbid obesity group and 1.1% of the patients in the nonmorbid obesity group had a diagnosis of a deep infection. Although our most common indication for rerevision in patients with morbid obesity was PJI, there also was an increased risk of rerevision for aseptic modes of failure. At the time of repeat revision, most implants included either sleeves or cones for enhanced metaphyseal fixation. Howard et al. [8] and Meneghini et al. [13] reported the respective short-term outcomes for use of femoral and tibial tantalum metaphyseal cones. There was radiographic component incorporation in all patients in their studies. As more longterm reports [10] become available, such techniques may prove to be good options for improved fixation in patients with morbid obesity.
In addition to having worse rerevision, reoperation, and infection rates, patients with morbid obesity had lower clinical outcome scores at all times. These results are comparable to those in a large registry study comparing clinical outcomes after primary TKA among patients in various BMI categories [1] . However, although overall outcomes were lower in our patients with morbid obesity, relative improvement between preoperative and postoperative scores was similar between groups, suggesting that repeat revision is helpful for patients with morbid obesity despite increased associated risks. Denying care to patients with morbid obesity would lead to worse outcomes in pain and function, especially with an already-failed TKA.
The care for patients with morbid obesity and knee arthritis remains challenging. Although there has been substantial contributions to the literature regarding the outcomes of knee arthroplasty in such patients in recent years, surgeons are left without guidance in terms of scientifically modifying treatment [1, 3-5, 11, 24] . In turn, surgeons have been left with two options: deny care or continue to operate despite the well-established risks. To meaningfully change the way we treat patients with morbid obesity, future studies first should aim to further riskstratify these patients with potential variables such as associated comorbidities, nutrition, and fat distribution. Once discrete risk factors are identified, we can attempt to meaningfully modify our care and improve patient outcomes.
Revision TKA remains a viable option for patients with morbid obesity and aseptic failure; however, the risks of implant failure, reoperation, and PJI are greater in patients with morbid obesity than those with a BMI less than 30 kg/ m 2 . The reasons for the increased risk are multifactorial and not yet fully understood. Because revision surgery cannot always wait for patient or comorbidity optimization, our outcomes emphasize the need for improving the care for patients with morbid obesity earlier during the osteoarthritic process. Additional studies are needed to risk stratify patients with morbid obesity to guide patient selection and effective optimization. The poorer outcomes after revision TKAs in patients with morbid obesity should be considered even before the index TKA.
